Soros Fund adds First Horizon, Horizon Therapeutics and bond ETF By Reuters

By Carolina Mandl

NEW YORK (Reuters) – Soros Fund Management, the family office of billionaire George Soros, added to its portfolio new shares in financial and healthcare companies and a bonds exchanged-traded fund in the fourth quarter, according to a regulatory filing on Monday.

Soros disclosed a $325.3 million stake, or 2.9 million shares, in biotech firm Horizon Therapeutics (NASDAQ:), which was bought by Amgen (NASDAQ:) in December for nearly $28 billion. It was the investment firm’s biggest singular acquisition in the quarter.

The firm also bought 2.8 million shares, valued at $90 million, in home health assessment firm Signify Health.

It added $209.1 million, or 8.5 million shares, in Memphis-based financial services company First Horizon (NYSE:), which was acquired by Toronto-Dominion Bank roughly a year ago for $13.4 billion. The deal has been delayed and now is expected to be concluded in May.

In finance, the investment firm also added consumer lending firm Capital One Financial Corp (NYSE:), Discover Financial Services (NYSE:), and SoFi Technologies, although it also dumped small investments in banks JPMorgan Chase & Co (NYSE:) and Bank of New York Mellon (NYSE:) Corp.

Soros’ portfolio dissolved or trimmed positions in tech companies.

Shares in Zoom Technologies Inc and Airbnb Inc were sold, while it reduced its holdings in Amazon.com (NASDAQ:), by 54.5%, to 901 million shares. Shares in the company rose 18.5% this year.

The regulatory filing also showed Soros bought $255 million in an investment grade corporate bond ETF.

The so-called 13-F filings, which disclose investment firms portfolios, are closely watched for investment trends even though the data is released with a delay and can be dated.

As interest rates rise, investors are increasing their bets on U.S. corporate bonds this year.